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In May 2012, Health Canada and other participants held a National Summit on Subsequent Entry Bio-
logics (SEBs). Health Canada released a guidance document in March 2010 describing policy positions
and data requirements for approval of SEBs. While Health Canada and health agencies in other regulatory
jurisdictions are aligned on many scientiﬁc principles related to biosimilar drugs, Health Canada’s
speciﬁc requirements may not be widely understood by many Canadian stakeholders. The Summit
provided an opportunity for education and dialog among physicians who prescribe biologics, provincial
payers, and industry on the following topics: preclinical and clinical comparability studies;
manufacturing and other product differences; extrapolation of indications; substitution and inter-
changeability of SEBs with reference biologic drugs in clinical practice; payers’ current perspective;
pharmacovigilance and naming. It is anticipated that the consensus reached at this meeting will further
educate Canadian healthcare professionals, provincial payers, and insurers about the appropriate use of
SEBs, and may be of general interest to others internationally.
 2012 The International Alliance for Biological Standardization. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
As patents on biologic drugs expire, biopharmaceutical
companies have been developing subsequent versions of originator
biologic agents. The term “biosimilar” has been coined to reﬂect
that these biologic drugs, which are produced in living systems, are
not identical to their respective reference products. Major health
agencies have held multilateral discussions on key scientiﬁc and
regulatory issues [1,2], and most jurisdictions have issued guidance
documents describing scientiﬁc principles and data requirementsy, Department of Medicine,
umatology Center, Memorial
nt St., Worcester, MA 01605,
(J. Kay).
gical Standardization. Published bfor the approval of these biosimilar drugs. The European Medicines
Agency (EMA) issued the ﬁrst guidelines in 2005 and 2006 [3,4].
The World Health Organization (WHO) and Health Canada issued
guidelines in 2009 and 2010, respectively [5,6]. The US Food and
Drug Administration (FDA) released draft guidelines in 2012 which
will be ﬁnalized after consideration of comments from stake-
holders [7,8].
While the above-named agencies are aligned on many scientiﬁc
principles related to biosimilar drugs (known as subsequent entry
biologics in Canada, or SEBs), and despite an extensive pre-
publication consultation process, Health Canada’s speciﬁc
requirements may not be widely understood by many Canadian
stakeholders. Provincial bodies and prescribers are facing impor-
tant questions such as interchangeability between SEBs and their
respective reference biologic drugs (RBDs), and only one SEB has
been approved in Canada to date (which occurred prior to they Elsevier Ltd. Open access under CC BY-NC-ND license.
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depth discussion and clariﬁcation of the scientiﬁc principles
applied by Health Canada in its guidance document would allow
prescribers and payers to make informed decisions in practice and
reimbursement as more SEBs enter the Canadian market.
In May 2012, Health Canada and BIOTECanada (the Industrial
Biotechnology Association of Canada) jointly organized a National
Summit on SEBs. Panelists (who are authors of this report) con-
sisted of directors and scientists from the review bureau of Health
Canada, clinical specialists who are prescribers of biologic drugs,
scientists who specialize in biologics manufacturing, pharmacoki-
netics (PK) and pharmacodynamics (PD), and also a reimbursement
specialist. In addition, over 20 observers attended the Summit,
including Health Canada reviewers and policy specialists, private
insurers and provincial payers, industry, academic scientists, the
Canadian Agency for Drugs and Technologies in Health (CADTH),
and the Government of Canada’s Patented Medicine Prices Review
Board.
2. Opening remarks
Dr. Kay (rheumatologist, UMass Memorial Medical Center,
University of Massachusetts Medical School) chaired the Summit
and openedwith an overview of regulatory aspects of biosimilars in
the European Union (EU) and the United States (US) to set the stage
for discussion of the regulatory pathway for approval of SEBs in
Canada.
Biosimilars, unlike small molecule drugs, are not generic
medicines, as they are not identical to their respective RBDs.
Preclinical and clinical studies must be carried out to demonstrate
that biosimilars and their RBDs have comparable efﬁcacy and
safety. Dr. Kay posed several key questions about biosimilars: Will
a biosimilar drug be as safe and effective as its RBD?Will dispensing
pharmacists be able to substitute a biosimilar for the RBD and could
this substitution adversely affect patients. Will the availability of
biosimilars reduce the cost of biologic therapies?
Dr. Kay provided an overview of the statutes governing the
licensure of biologic drugs in the US [reviewed in [11,12]]. The
Patient Protection and Affordable Care Act of 2010 was signed into
law on March 22, 2010. Section 7002 of this statute, called the
Biologics Price Competition and Innovation Act (BPCIA) of 2009
created an abbreviated Biological Licensing Application for highly
similar biologic products. Dr. Kay reviewed the pathway for
approval of a biosimilar, consisting of non-clinical and clinical
studies and post-marketing pharmacovigilance monitoring, that is
speciﬁed in the Act.
Dr. Kay also reviewed EMA guidelines for the approval of bio-
similars, including the non-clinical and clinical studies and post-
marketing commitments that are required of biosimilar manufac-
turers [3,4]. In addition, he reviewed the EMA draft guideline for
assessment and approval of biosimilar monoclonal antibodies
(mAbs) [13].
Dr. Kay focused on the aspect of interchangeability as deﬁned by
the BPCIA. According to the BPCIA, a biological product can be
deemed interchangeable with a reference product only if it is
“biosimilar to the reference product” and “can be expected to
produce the same clinical result as the reference product in any
given patient.” Also, “the risk in terms of safety or diminished
efﬁcacy of alternating or switching between the biosimilar and the
reference product [must not be] greater than the risk of using the
reference product without such alternation or switch.” He high-
lighted that a clinical trial to meet these criteria must be designed
to demonstrate that patients switching repeatedly between the
two biologic drugs would not experience greater safety risk than
patients receiving the biosimilar or the RBD alone withoutswitching. Such a study presumably would involve multiple
switches between the RBD and biosimilar. Dr. Kay considered that,
because such a study might put subjects in the experimental group
at risk for developing antibodies to either or both biologic drugs
without providing beneﬁt beyond that experienced by control
subjects receiving the RBD, institutional review boards might view
the study design as unethical because of an unacceptable risk-
beneﬁt ratio.
Interchangeability between biologic drugs is much more prob-
lematic than interchangeability between small molecule drugs. Dr.
Kay highlighted that a patient who is switched between two bio-
logic drugs might develop anti-drug antibodies (caused by small
differences in post-translational modiﬁcations of the proteins and/
or product/process-related impurities), which could compromise
efﬁcacy and safety. Such immunogenicity was observed when
EPREX underwent a change in formulation that resulted in the
induction of antibodies to erythropoietin, possibly caused by
leachates from the rubber stopper of the syringe. The development
of antibodies to this non-redundant hormone resulted in over 200
cases of pure red cell aplasia [14,15].
Dr. Kay stated that the draft FDA guidance does not specify
requirements for the clinical trial size, duration or non-inferiority
versus equivalence design [7,8]. If there is sufﬁcient scientiﬁc
justiﬁcation, the FDA may allow data from a clinical trial of the
biosimilar in one disease to be used to support approval of the
biosimilar for other indications for which the RBD is already
licensed (e.g., if the biologic drug has the samemechanism of action
in these disease states). Dr. Kay raised a potential problem with
such data extrapolation. For example, ENBREL is licensed for the
treatment of rheumatoid arthritis at 50 mg per week but must be
used at double that dose (50mg twiceweekly) to achieve efﬁcacy in
psoriasis. Thus, could a biosimilar etanercept be deemed effective
for treating psoriasis based on a clinical trial in rheumatoid
arthritis, given that the effective doses of ENBREL are different in
the two diseases?
Dr. Kay concluded by stating that the details of how the FDAwill
implement the abbreviated pathway for approval of biosimilars
created by the BPCIA are still being worked out, and that no bio-
similar has yet been approved in the US using this regulatory
pathway.
3. Overview of Canadian guidance and international update
Dr. Nyarko (Ofﬁce of Policy and International Collaboration,
Health Canada) provided an overview of the Canadian guidance on
SEBs and clariﬁed a number of critical aspects. Dr. Nyarko stated
that Health Canada uses a science-based, pragmatic approach to the
evaluation of SEBs, and that this approach is aligned with inter-
national best-practice guidelines to which Health Canada has
contributed.
Health Canada’s deﬁnition of an SEB is a drug that would enter
the market subsequent to a named reference drug to which it
would be similar. Both conditions (i.e., “subsequent to” and “similar
to” the RBD) must be met. The approval of an SEB will rely, in part,
on information about the RBD for the demonstration of similarity.
The SEB sponsor is responsible for providing the necessary
evidence to support all aspects of an application for establishing
biosimilarity and achieving marketing authorization. Health
Canada will not assist an SEB sponsor by providing any information
from the dossiers of an approved RBD. Many characteristics of the
marketing authorization process and marketed use of generic
pharmaceutical drugs do not apply to SEBs. Therefore, the autho-
rization of an SEB is not a declaration of pharmaceutical or thera-
peutic equivalence to the RBD. Since the submission of an SEB
involves a comparison to an RBD, the principles of intellectual
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submissions.
Once a Notice of Compliance (approval/marketing authoriza-
tion) is issued, the SEB will be regulated as a stand-alone biologic
drug similarly to an innovator biologic drug. Therefore, once the
SEB is approved, any subsequent changes to the RBD will not
automatically apply to the SEB. The SEB would require relevant
clinical and non-clinical data to support any additional changes to
the product monograph.
The evaluation of an SEB involves a side-by-side demonstration
of similarity to the RBD. A full chemistry and manufacturing data
package is required, plus an extensive side-by-side characterization
of the SEB and RBD as per the principles of ICH Q6B [16]. The
comparability principles outlined in ICH Q5E also apply [17]. The
results of the comparability exercise should demonstrate a high
degree of similarity between the SEB and RBD and will determine
the extent of additional non-clinical and clinical investigations
required. Therefore, an SEB should be developed (and evaluated) in
a stepwise manner.
Dr. Nyarko stated that comparative non-clinical and clinical
studies should be designed to detect any differences between the
SEB and RBD. Health Canada recommends conducting non-clinical
studies prior to the design and initiation of clinical studies. Clinical
studies should be provided for each indication being sought, and
must have statistical power to detect major differences in safety. In
justiﬁed cases, a comparative PK/PD data package to bridge two or
more indications may be sufﬁcient.
As per Health Canada’s guidance, safety data from a sufﬁcient
number of patients in a study of sufﬁcient duration should be
provided to compare the nature, severity, and frequency of adverse
reactions between the SEB and RBD. The immunogenicity of the
SEB should be tested using state-of-the-art methods in terms of its
effects on both efﬁcacy and safety. In cases where a high degree of
similarity between the SEB and RBD cannot be established, Health
Canada will not consider the SEB biosimilar to the RBD, and a full
dossier including complete non-clinical and clinical data will be
required for approval.
A ﬁnal determination of similarity will be based on a combina-
tion of analytical testing, biological assays, and non-clinical and
clinical data. The demonstration of comparability does not neces-
sarily mean the quality attributes of the two products are identical,
only that they are highly similar. A decision to issue a Notice of
Compliance is based on a risk-beneﬁt assessment after considering
all of the safety, quality and efﬁcacy data submitted by the sponsor.
The same principle is applied during review of any medicinal
product. In a manner consistent with Health Canada, FDA describes
this approach as considering the totality of the evidence.
The indications granted to an SEB in Canadawill be based ondata
provided by the SEB sponsor. If the sponsor does not provide sufﬁ-
cient data, the SEB will not automatically be approved for all indi-
cations held by the RBD. Furthermore, if the SEB sponsor applies for
indications not approved for the RBD, full clinical trial data packages
are required. Authorization of an SEB is not a declaration of inter-
changeability or substitutability between the SEB and RBD.
A Risk Management Plan (RMP) for an SEB should be presented
to Health Canada prior to marketing authorization. Plans for
monitoring immunogenicity, inherent safety concerns, and
unknown safety signals that could result from the impurity proﬁle
and other characteristics of the SEB should be agreed upon. Adverse
reactions are reported as required by the Food and Drug Regula-
tions as is the case for any other medicinal product. Submission of
Periodic Safety Update Reports (PSURs) will be required as per ICH
E2E guidelines.
With respect to harmonization of regulations among regulatory
jurisdictions, Dr. Nyarko commented that Health Canada, EMA anddraft FDA guidelines follow many of the same scientiﬁc principles
[3,4,6e8].WHO guidancewas released around the same time as the
Health Canada guidance, and WHO continues to conduct imple-
mentation activities and workshops so that other regulators can
adapt theWHO guidance as appropriate [5]. He provided an update
on a Biosimilars Workshop held at a recent international APEC
Harmonization Centre Conference in Seoul, Korea, which was
attended by several International Regulators as well as industry
[18]. Discussions conﬁrmed that the scientiﬁc principles for eval-
uation of biosimilars are consistent among most regulatory
authorities, and that the Canadian guidance on the use of reference
products not approved in the country of ﬁling is being adopted
internationally.
Acknowledging the lack of major safety concerns to date for
biosimilar products approved in the EU, Dr. Nyarko clariﬁed that
some products on the global market do not meet the Canadian,
European or US criteria for SEBs, and highlighted the need for
caution around deﬁnitions of the term biosimilar. A biosimilar or
SEB as deﬁned by Health Canada is based on the comparability
exercise at the product quality level. In contrast, some subsequent
entry products available on the global market have not demon-
strated a high degree of comparability yet are still referred to as
biosimilar.4. How similar is similar? Manufacturing considerations
Dr. Lubiniecki (Janssen Pharmaceutical Companies of Johnson &
Johnson) discussed the fact that, compared to small molecule
drugs, biologic drugs are much larger in size and have more
complex molecular structures. As a result, millions of different
chemical forms of active ingredient can be present in a biologic
drug product. For example, the 527-amino acid tissue plasminogen
activator (tPA) protein, with its 17 disulphide bridges and 3 glyco-
sylation sites, may contain more than 1 billion chemically distinct
active ingredient molecules in the ﬁnal drug product. Analytical
tools are limited in their ability to accurately monitor all possible
variations of biologic products; therefore, a high degree of process
control is required to ensure product quality and consistency. In
contrast to biologic products, typically 95 percent of the active
ingredient molecules in a small molecule product are chemically
identical. Also, the interactions between small molecules and their
binding targets cover a much smaller surface area than those of
biologic products and their receptors, highlighting the importance
of proper three-dimensional structure and surface characteristics of
biologic drugs. Therefore, SEBs are not analogous to small molecule
generics.
Dr. Lubiniecki discussed the limitation of the available guide-
lines for deﬁning the comparability of SEBs. ICH Q6Bmainly deﬁnes
product speciﬁcations, whereas ICH Q5E is the comparability
guideline for demonstrating that product attributes remain highly
similar following changes in raw materials, manufacturing unit
operations, critical process parameters or manufacturing sites
[16,17]. Dr. Lubiniecki noted that the comparability practice as
described within ICH Q5E applies to a single product before and
after process changes within a single manufacturer. ICH Q5E would
not sufﬁciently cover differences in the manufacturing process of
the SEB compared to that of the RBD including expression system
(host cell type, species, clonal isolate), recombinant DNA plasmid,
fermentation system (media, vessel, environmental conditions),
control strategy, and puriﬁcation process (unit operations, chro-
matography, resins, buffers). The process-related and product-
related impurities of the SEB will not be identical to those of the
RBD, and the SEB and RBD may or may not be biosimilar. Other
potential differences in the SEB include formulation, container-
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manufacturer.
Dr. Lubiniecki addressed the notion of an acceptable level of
difference between an SEB and RBD, asking whether the absence of
detectable differences due to lack of adequate detection methods
could be misinterpreted as evidence of biosimilarity. Furthermore,
the methods used to deﬁne adequate biosimilarity may be product-
speciﬁc. Deﬁning acceptable levels of biosimilarity will depend on
knowledge of structureefunction relationships and mechanisms of
action for different indications, as well as mechanisms of toxicity.
Dr. Lubiniecki described examples of erythropoietin products
marketed in Asia, India, and Argentina subsequent to innovator
erythropoietin that may not meet the standards for biosimilarity as
deﬁned by some regulatory jurisdictions. These products exhibited
differences in charge, in vivo potency, sialic acid content, batch-to-
batch properties, impurities, cell line, and unfolded protein content
[19e22].
Dr. Lubiniecki discussed examples of so-called biosimilars of tPA
(India) and trastuzumab (China) that have differences in carbohy-
drate forms and primary sequence as well as other differences
when compared to their RBDs [23,24]. Previous work on tissue
plasminogen activator has shown that these differences affect
potency in animals. Due to the number of possible mechanisms of
action for mAbs in particular (e.g., antigen binding and Fc-mediated
accessory functions), it is not possible to predict the clinical impact
of observed differences; therefore, some clinical impact might be
expected.
Dr. Lubiniecki concluded that no matter how similar to an RBD
an SEB appears to be, there is residual, un-discharged risk that the
SEB will have a different proﬁle of safety and efﬁcacy. Therefore,
appropriate non-clinical and clinical studies are required to miti-
gate the residual risk. In addition, if the SEB sponsor has deliber-
ately introduced changes to the protein sequence, to the
formulation, or to the container closure system then there are
further risks of clinical differences. In these instances, the appro-
priate regulatory pathway may be that of a New Drug Submission.
Dr. Ridgway (Centre for Evaluation of Radiopharmaceuticals and
Biotherapeutics, Health Canada) stated that the regulatory
approach of Health Canada to biosimilars is based on concepts of
comparability and the importance of product characterization. The
motivation within Health Canada to develop guidance for the
evaluation of SEBs was neither political nor ﬁnancial. Rather,
acknowledgment of the need for a science-based, practical
approach to review pending submissions for SEB products
prompted development of the guidance.
Dr. Ridgway stated that for some biologics, there are multiple
innovator versions that are safe, effective, and non-identical;
therefore, he reasoned that some differences between products
are not critical. Innovators also make manufacturing changes with
minimal or no supporting clinical data. As a result, Health Canada
has used the comparability exercise undertaken by innovators after
a manufacturing change as a model for biosimilar comparability,
and adapted international guidance (especially from ICH including
Q5E and Q6B) for this purpose [16,17]. The studies required to
determine whether a product undergoing a manufacturing change
is equivalent to the product prior to the change will depend on the
stage at which the changes are introduced, the impact or potential
impact on the product, analytical limitations, and the link between
the quality criteria and possible implications on safety and efﬁcacy.
To address these issues, the ICH developed the Q5E guideline.
While Q5E applies only to changes within one manufacturer,
Dr. Ridgway commented that much of the guidance is relevant to
SEBs. One of the general principles of the guideline is that “the
demonstration of comparability does not necessarily mean that the
quality attributes of the pre-change and post-change product areidentical but that they are highly similar and that the existing
knowledge is sufﬁciently predictive to ensure that any differences
in quality attributes have no adverse impact upon the safety or
efﬁcacy of the drug product”; therefore, the previously derived
clinical data are still relevant. If comparability is not established,
more extensive clinical trials are usually requested.
To date, ﬁve different types of products have been approved in
Europe as biosimilars. Dr. Ridgway commented that he is not aware
of any major adverse events or withdrawals associated with these
products, to date. The European review system also identiﬁed
products that did not meet standards for biosimilarity, such as an
interferon-alpha product by Alpheon (due to impurities, adverse
events, and clinical relapse) and insulin products by Marvel (not
clinically comparable) [25,26]. These examples demonstrate the
value of going beyond the chemistry and manufacturing data to
assess safety and efﬁcacy in patients.
Dr. Ridgway commented that the weight of the evidence to
determine whether a product will be considered biosimilar will be
provided by the product quality studies. It is going to be a great
advantage if the sponsor uses a similar manufacturing process to
that of the RBD. Signiﬁcant differences and gaps in the product
quality determinations cannot be ﬁlled in by a demonstration of
clinical similarity.
All bioactivities and associated critical quality attributes of the
molecule should be assessed. Different parts of some molecules
have different activities and contribute in different ways to clinical
efﬁcacy, and some of these may be more or less important in
different clinical indications. It is not acceptable to focus only on the
part of themolecule that is important for the clinical indication that
one is interested in. The whole molecule must be evaluated and
shown to be similar.
To avoid the need for an internal comparability bridging study,
the SEB material used in clinical trials should be from the
commercial process and the same material used in the quality and
non-clinical studies. Process changes late in development should
also be avoided.
For comparability studies, Health Canada recommends that
sponsors obtain different lots of the RBD (e.g., with different expiry
dates), with documentation of purchase locations which may
reﬂect where the product has been manufactured. The assessment
of inter-batch variability of the RBD may help support an assess-
ment of similarity for the SEB. This approach does not imply that
every test should be performed on every batch; a matrix approach
could be rationalized.
Comparability tests should be selected and optimized to maxi-
mize the potential for detecting relevant differences in quality
attributes. Also, more than one analytical procedure should be used
to evaluate the same attribute in order to maximize the possibility
that any differences will be detected. Stability data, including data
from accelerated or stress conditions, can provide insight into
potential product differences in the degradation pathways of the
drug product and, hence, potential differences in product-related
substances and product-related impurities.
Dr. Ridgway discussed a study in which multiple lots of biologic
products (RITUXAN and ENBREL) were characterized by
a company developing biosimilars (Sandoz Biopharmaceuticals)
[27]. The products were purchased over an extended period to try
to obtain product from different manufacturing batches. The
approach appeared to capture the products before and after
manufacturing changes, and differences were detected using
several analytical methods. Such changes to a product over time are
known as “manufacturing drift.”Manufacturing drift may affect the
similarity of an SEB to an RBD over time, and, although the products
may be similar at the time of approval of the SEB, they may not be
similar after introduction of subtle changes to either product. The
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Therefore, “once granted a Notice of Compliance, an SEB is
considered to be a new (‘stand-alone’) product with all of the
associated regulatory requirements” [6] and, from a regulatory
standpoint, is not considered interchangeable/substitutable with
the RBD. Furthermore, a demonstration of similarity or therapeutic
interchangeability supported by speciﬁcally designed clinical
studies would only be valid at the time the datawere generated due
to possible manufacturing drift of either product over time. The
position of Health Canada is that, while it is appropriate for
a physician to substitute or prescribe an SEB for a patient for an
approved clinical indication, the SEB should not be substituted
automatically. SEBs in Canada will not be labeled interchangeable
with RBDs.
SEBs, once approved,would be regarded as stand-alone products
and may later gain approval for additional strengths, dosage forms,
and clinical indications if substantiated by a full supportive dossier.
Such products with different strengths, presentations, and indica-
tions would also not necessarily be interchangeable with the RBD.5. Clinical perspectives: clinical study design, sensitive
patient populations, extrapolation of indications,
immunogenicity
Dr. Feagan (gastroenterologist, Robarts Research Institute,
University of Western Ontario) described the prevalence of
inﬂammatory bowel diseases in Canada, and commented that
monoclonal antibodies have improved treatment options for
patients, especially in Canada, which is one of the largest users of
monoclonal antibodies in gastroenterology on a per capita basis.
The PK of monoclonal antibodies is complex, and can be affected
by co-administration of antimetabolites such as methotrexate and
azathioprine which can affect clearance as well as immune
responses to drug (when patients develop anti-drug antibodies).
Anti-drug antibodies can also affect PD and clinical efﬁcacy.
Therefore, Dr. Feagan commented that differences between mole-
cules (e.g., SEB versus RBD) can have consequences in terms of PK,
PD, and immunogenicity.
Dr. Feagan presented clinical ﬁndings that development of
higher titers of anti-drug antibodies to inﬂiximab or adalimumab
correlates with shorter duration of response and higher incidence
of infusion reactions [28,29]. Also, co-administration of antime-
tabolites with inﬂiximab reduces the risk of developing neutral-
izing antibodies and increases trough levels of drug [30]. In the near
future, gastroenterologists will have access to assays that can detect
therapeutic antibodies in clinical samples. Dr. Feagan suggested
that speciﬁc assays could be developed for each biosimilar, thereby
allowing clinicians to evaluate treatment decisions based on the
serum levels of the therapeutic antibody as well as anti-drug
antibodies, as previously described [31].
Dr. Feagan used the examples of abatacept and etanercept,
which have similar efﬁcacy in rheumatoid arthritis but not in
Crohn’s disease, to reason that extrapolation of indications should
not be permitted [32]. He added that the mechanisms of action of
the TNFa antagonists are not completely understood, and that
subtle molecular differences in a biologic drug may alter binding
to targets in the body and lead to different clinical effects.
For example, etanercept, adalimumab, and inﬂiximab avidly bind
soluble TNFa and induce reverse signaling through membrane-
bound TNFa. However, the signaling effects induced by the three
molecules are quantitatively and qualitatively different [33]. Which
of the downstream effects contribute to efﬁcacy in various disease
states is not known; therefore, Dr. Feagan questioned the validity of
pharmacodynamic markers for anti-TNFa agents.Dr. Feagan concluded with a discussion of the size of clinical
trials required to evaluate the equivalence or non-inferiority of an
SEB versus an RBD. He suggested that a margin of effect of 15% in
a superiority trial would require 300 patients, and a margin of 7.5%
in a non-inferiority trial would require 1500 patients. He expressed
concern about whether large biosimilar trials could be conducted
alongside trials for new innovator compounds in limited patient
populations.
Dr. Wang (Clinical Evaluation Division e Hematology/Oncology,
Health Canada) discussed the regulatory perspective on deﬁning
a sensitive population for clinical studies, and on extrapolation of
indications. To determine whether an SEB achieves an acceptable
level of similarity, Health Canada must evaluate whether any
differences in quality between the SEB and RBD could affect safety
and efﬁcacy. Dr. Wang described that the quality data package for
an SEB includes comparability data between the RBD and SEB in
addition to the usual requirements for an innovator product.
However, because the clinical data package for an SEB is not as
extensive, a patient population that is most sensitive should be
selected and the patient number must be large enough to detect
meaningful differences in safety, efﬁcacy, and immunogenicity. Dr.
Wang emphasized that Health Canada should be consulted
regarding the design of clinical trials as well as the selection of
a sensitive population prior to the trial getting underway. He
explained that in a sensitive population, differences between an
SEB and RBD can bemore easily detected. Both healthy subjects and
patients could be considered sensitive populations for different
stages of clinical assessment depending on the questions at hand.
Dr. Wang cautioned that healthy subjects may not be considered
a sensitive population when a clinically relevant dose may induce
a ceiling effect in the clinical response (i.e., because subjects have
intact physiological function), or when a targeted effect of
a monoclonal antibody is being studied. A study in a healthy pop-
ulation may be used to demonstrate doseeresponse relationships.
For such a study, a dose in the steep part of the curve should be
chosen to avoid masking effects.
Only in well-justiﬁed cases, a properly conducted clinical study
in a sensitive population may allow for extrapolation to other
indications for which the Canadian RBD is approved. Various
aspects of clinical trial design may impact whether the data are
adequate to support extrapolation. These design features include
the population being studied, duration of the trial, route of
administration, dose, monotherapy versus combination therapy,
concomitant medications, and immunogenicity proﬁle. A PK/PD
bridging study in the relevant patient population is also required.
Dr. Wang elaborated that extrapolation of indications may not be
possible in some cases. For example, RITUXAN has indications in
rheumatoid arthritis, oncology, and vasculitis due to the involvement
of CD20 in all of these diseases; however, the underlying patho-
physiology and mechanism of action may not be the same,
making extrapolation of indications for this product very challenging.
He added that extrapolations in the following cases may be difﬁcult
to justify: different routes of administration (from intravenous to
subcutaneous), from pharmacodynamic biomarker to clinical
endpoint, from short to long-term use, from combination therapy to
monotherapy, from high to low dose, from one to both genders, and
from healthy subjects to a disease population. It may be more
acceptable to extrapolate frommonotherapy to combination therapy
once comparable safety and efﬁcacy of SEB monotherapy has been
established. A particular area of concern is the immunogenicity of the
subcutaneous route of administration; it may be more acceptable to
extrapolate from subcutaneous administration to indications
requiring intravenous administration, rather than the reverse.
Dr. Keystone (rheumatologist, Mount Sinai Hospital/University
Health Network, University of Toronto) considered that even
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mumab, etanercept, golimumab, and inﬂiximab exhibit similar
clinical efﬁcacy in terms of their main clinical trial endpoints in
rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Therefore, he reasoned that the typical clinical trial endpoints for
these indications (e.g., ACR20, ASAS20, and PASI75) are inadequate
to assess differences between SEBs and their respective RBDs, and
highlighted the importance of conducting clinical trials for SEBs in
a sensitive clinical population.
Dr. Keystone highlighted that different doses of etanercept are
used to treat rheumatoid arthritis and plaque psoriasis. He also
drew attention to the differences in approved indications between
the anti-TNFa mAbs, and that etanercept, unlike adalimumab and
inﬂiximab, has not demonstrated efﬁcacy in Crohn’s disease. The
reason for this discrepancy, besides their molecular differences, is
unknown. Dr. Keystone summarized the differences in sequence
and structure among the anti-TNFa agents. Certolizumab pegol,
a pegylated Fab’ fragment [34], lacks an Fc domain (which has been
proposed to contribute to the mechanism of action of anti-TNFa
drugs in Crohn’s disease) and yet still exhibits efﬁcacy in Crohn’s
disease. Taken together, the issues with certolizumab pegol and
etanercept suggest that the mechanism of action of anti-TNFa
agents in Crohn’s disease is not completely understood.
Dr. Keystone stated that the immunogenicity of TNFa antago-
nists can negatively impact safety, efﬁcacy, drug levels and potency,
and therapeutic switching strategies. As observed in the ATTRACT
and ACCENT I trials of inﬂiximab in rheumatoid arthritis and
Crohn’s disease, respectively, the presence of anti-drug antibodies
was associated with a higher proportion of infusion reactions
[35,36]. Also, the presence of antibodies to adalimumab has been
associated with lack of response and lower trough levels of drug in
serum in patients with rheumatoid arthritis, as well as lack of PASI
response in patients with psoriatic arthritis [37,38]. Similar effects
have been reported in patients with Crohn’s disease treated with
inﬂiximab. Dr. Keystone also mentioned a recent study suggesting
that anti-drug antibody responses to inﬂiximab are associated with
a higher level of anti-drug antibody response after switching to
adalimumab, even though these anti-drug antibodies are not cross-
reactive [39]. Dr. Keystone suggested that patients losing response
to one therapy could bemonitored for anti-drug antibodies to guide
decisions about the next course of therapy. A similar approach
could be developed for SEBs.
6. Clinical perspectives: pharmacokinetics,
pharmacodynamics
Dr. Mould (Projections Research Inc.) reviewed the require-
ments for comparative PK and PD studies as described in Health
Canada’s guidance document. She commented that human PK and
PD proﬁles cannot always be predicted from functional assays and/
or animal studies, and cautioned that animals may not always be
suitable models of human antibody salvage pathways (through
interaction with FcRn), target receptor interactions, or cytokines. A
human PD study demonstrating similar effects on a clinically
relevant PD measure could provide strong support for bio-
similarity; however, with respect to the inﬂammatory diseases
treated with anti-TNFa mAbs, the biomarkers of disease, including
C-reactive protein, are not well-correlated to clinical efﬁcacy and
thus are not considered appropriate surrogate endpoints.
Dr. Mould discussed the selection of suitable subjects (patients
or healthy volunteers) for PK and PD studies. Dr. Mould suggested
that for alemtuzumab (CAMPATH, anti-CD52 antibody), which is
used to treat B-CLL, PK in healthy volunteers and patients would be
quite different. In healthy volunteers who express low levels of the
target receptor, PK would appear to be linear and exhibit a half-lifetypical of IgG antibodies. In contrast, patients in blast crisis would
exhibit low levels of drug soon after administration because of
receptor mediated clearance [40]. Dr. Mould noted other examples
of the variable PK of anti-TNFa antibodies in different patient
populations, including patients who develop anti-drug antibodies.
Dr. Mould suggested that disease-PK interactions, whereby
levels of drug can vary in different disease states, may complicate
extrapolation of PK data from one disease state to another [41]. She
stated that it would be a very rare case that a demonstration of
biosimilarity could be made on human PK and PD data alone, and
that comparative safety and efﬁcacy studies may be necessary to
resolve any residual uncertainties about the similarity of two
products. Dr. Mould suggested that the following factors could
inﬂuence the type and extent of comparative clinical safety studies
required: the nature and complexity of the reference product;
limitations in comparing structural and functional characteristics;
the ﬁndings of non-clinical testing; the extent that differences in
structure, function, and non-clinical pharmacology and toxicology
can predict clinical outcomes; the degree of understanding of
mechanism of action of the reference product and disease
pathology; the extent that human PK/PD can predict clinical
outcomes; and the extent of clinical experience with the RBD
including safety, efﬁcacy, and relevant biomarkers.
Dr. Mould discussed the example of pegﬁlgrastim (NEULASTA).
While manufacturing controls are in place, variability in the extent
of pegylation and types of pegylation in the product can affect
clinical PK and PD. Pegylation reduces the recognition of the
product as a foreign protein and slows proteolysis but also inter-
feres with the analysis of drug levels. For these reasons, demon-
strations of comparability for a pegylated SEB product may be
difﬁcult.
Dr. Mould reiterated previous comments that due to partial
understanding of themechanism of action of products such as TNFa
antagonists in different disease states, data in one indication may
not apply to other indications. Dr. Mould also identiﬁed the
example of cetuximab (ERBITUX, anti-EGFR), which has activity in
several solid tumor types, and even in tumors where the target of
the antibody has not been detected [42].
Dr. Mould added that antibodies engineered to bind very well
with FcRn will have longer half-lives. She commented that FcRn
expression and receptor mediated clearance of antibodies can vary
among different subjects and disease states. For example, in
patients with multiple myeloma in whom IgG levels are high, FcRn
receptors are saturated, compromising the salvage pathway, which
can result in a very short IgG half-life. Also, expression levels of
antibody targets can vary in different patient populations. Dr.
Mould described an example in which levels of a targeted mAb in
a patient with B-cell lymphoma were very low early during the
course of treatment when white blood cell (WBC) counts were
high; once WBC levels decreased in response to drug, the mAb
could then be readily detected in serum [40]. In these circum-
stances, subcutaneous administration of such a drug would not
result in detectable levels in serum until the patient achieved good
response.
Dr. Mould emphasized that it would be challenging to extrapo-
late PK for a mAb in one patient population to another, and that
switching routes of administration even for the same drug in the
same patient population can result inmarkedly different PK and PD.
Dr. Mould concluded that the determination of similarity is
a complex process. It is important to understand the pharmacology
and the impact of disease on PK/PD. Dr. Mould suggested that
sponsors should incorporate information about endogenous factors
that can affect PK and PD.
Dr. Wang reviewed the differences in Health Canada’s require-
ments for small molecule generics and SEBs. For generic
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administered intravenously. In contrast, an SEB application requires
bioequivalence and PD/clinical comparability studies as part of the
stepwise comparability assessment. Generics receive a claim of
equivalence in the product labeling, whereas SEBs, which are not
identical to their RBDs, will be labeled as similar. Furthermore, it is
not appropriate to refer to SEBs and RBDs as pharmaceutically
equivalent.
Dr. Wang reviewed the potential uses of PK/PD studies in an SEB
application: to support a demonstration of similarity between an
SEB and RBD, to monitor immunogenicity, to quantify the effects in
patient populations, to compare different formulations of an SEB, or
to compare different routes of administration of an SEB. Further-
more, Dr. Wang reviewed factors to consider when designing PK/PD
studies, such as half-life, linearity of PK, endogenous levels and
diurnal variations of the protein under study (comparability testing
would be speciﬁc to exogenous levels of a biologic drug), the
disease being treated, route of administration, the indications for
which the sponsor is applying, and, particularly for mAbs, elimi-
nation pathways including target-mediated pathways (which
depend on the expression levels of the target).
Dr. Wang stated that comparative PK studies should be con-
ducted to detect potential differences between the SEB and RBD by
performing single-dose, cross-over studies in sensitive, homoge-
nous populations using a dose that is most sensitive to detect
differences through subcutaneous or intramuscular routes of
administration. For cross-over studies, sponsors need to justify that
drug half-life is not an issue and that formation of antibodies does
not impact the PK/PD proﬁle. Dr. Wang added that a parallel group
design should be considered for SEBs with a long half-life, and that
the two groups should be balanced. He emphasized that parallel PK
study designs require more subjects than cross-over designs in
order to achieve statistical power. For drugs with a long half-life or
that are administered intravenously, a demonstration of similarity
in absorption or bioavailability may not be available or sufﬁcient.
Furthermore, a demonstration of similarity in clearance and half-
life may be required for assessing the risk of differences in elimi-
nation rate for these products.
Dr. Wang advised that PK studies should generally be conducted
in the relevant patient population, since a number of factors such as
receptor expression, receptor internalization rate, and patient
condition can affect the clearance of the medicinal product. He
further clariﬁed the limitations of conducting studies in healthy
patients although sometimes this approach could be justiﬁed.
Healthy subjects would not likely support data extrapolation to
disease states, and healthy subjects may not be considered themost
sensitive population because a clinically relevant dose may induce
a ceiling effect. Also, target-mediated effects on PK cannot be fully
assessed in healthy subjects.
With respect to the parameters for PK comparability, Dr. Wang
stated that the principles for small molecules (for example, 90
percent conﬁdence interval for AUCT and ratio of test to reference
Cmax to bewithin 80e125 percent) may not always apply to biologic
products. For PD studies, biomarkers or clinically relevant and
validated surrogate markers can be used. Dr. Wang stated that
combined PK/PD studies may provide useful information on the
relationship between dose exposure and effect, and could be used
to support extrapolation of indications. He highlighted that the
PD parameters could be investigated in the context of
combination PK/PD studies. Dr. Wang clariﬁed that Health Canada
recommends 95 percent instead of 90 percent conﬁdence
intervals for PK/PD studies when determining similarity for SEBs.
He also stated that well-designed comparative PK/PD studies may
be sufﬁcient to demonstrate clinical comparability in cases where
sufﬁcient justiﬁcation is provided.7. Post-market: payer perspective
Dr. Guirguis (Alberta Blue Cross, presenting his personal view,
not that of his employer) expressed concern about the challenges
that face prescribers and payers to ensure the safe and effective use
of SEBs. While these important stakeholders are aware that SEBs
are not generic products, there remains a degree of uncertainty
about them in general, which is reﬂected by the terminology used
and the complexity of discussion. Dr. Guirguis stated that given the
current knowledge gap regarding substitution and interchange-
ability of SEBs, payers and governments would be hesitant to
impose restrictions on physicians and patients.
Dr. Guirguis perceived a lack of understanding among
prescribers and payers about differences in manufacturing, PK and
PD between SEBs and their respective RBDs. He pointed out that
regulators are trying to quantify this variability and deﬁne
acceptable levels of risk. For example, statistical intervals are used
as goalposts for PK and PD measurements, and release tests for
manufacturing variability. He questioned the understanding at the
prescriber level of risk associated with differences between SEBs
and RBDs, and how that could be communicated and managed. He
raised the issue that long-term safety data should be required to
determine whether SEBs and RBDs will be comparable over time.
Other factors for consideration by physicians are whether an SEB
comes with a different delivery device, whether it has a similar
patient support program as the RBD, and whether patients will
require more frequent follow-up. He discussed the uncertainty
a physician could face in the event of lack of efﬁcacy in a patient
receiving an SEB, as well as the lack of clinical data on whether the
patient could beneﬁt from a switch to the innovator product.
Dr. Guirguis stated that as costs for biologics increase, entry of
SEBs into the Canadianmarket may result in signiﬁcant cost savings
for payers and insurers. However, he commented that the market
penetration of follow-on proteins and biosimilars in other markets
has not been very high and suggested several possible explana-
tions: issues related to speciﬁc products, cultural issues, and
actions/perceptions of prescribers and patients. He reasoned that
there is a need, while not dictating prescribing practices, to provide
patients and physicians with information so that they can make
informed treatment decisions.
8. Post-market: pharmacovigilance and safety monitoring
Dr. Klein (Centre for Evaluation of Radiopharmaceuticals and
Biotherapeutics, Health Canada) remarked that Health Canada
takes a scientiﬁc approach to reviewing SEBs. She emphasized that
an SEB is not identical to its RBD. At the time of marketing autho-
rization, as much if not more information will be available for an
SEB than for other newly approved products; however, important
concerns such as immunogenicity and other safety issues remain
unknown and need to be deﬁned for the SEB. Hence, there is a need
for post-marketing pharmacovigilance for SEBs.
The pharmacovigilance requirements for SEBs will be similar to
those for novel biologic products with respect to adverse event
reporting, Periodic Safety Update Reports (PSURs) and additional
post-marketing surveillance activities. Sponsors are required to
submit a Risk Management Plan (RMP), which is a prospective set
of safety mitigation standards tailored to concerns about the
product. The content of the RMP should be agreed upon by the
Regulator and the sponsor before marketing authorization is
granted. The requirements for ad hoc reporting and other regula-
tory actions are the same as those for novel innovator products.
Like any new medicinal product, SEBs will be closely monitored
in the post-marketing phase due to incomplete information at the
time of marketing authorization. The objective of post-market
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immunogenicity proﬁle and local reactions. Since SEBs and RBDs
are not identical, their properties could differ widely. Dr. Klein
highlighted that biologic products vary from time to time and
cannot be reproduced in an identical manner over time. Thus,
Health Canada is taking a lifecycle management approach to the
regulation of medicinal products, allowing the knowledge about
particular products to be less static than it has been in the past.
Dr. Klein clariﬁed Health Canada’s position on substitution and
interchangeability: SEBs and RBDs are not substitutable products.
Secondly, matters of interchangeability and substitutability are
under the jurisdiction of the Canadian provinces, not that of the
federal government.
9. Discussion
The following section is an edited synopsis of key issues dis-
cussed during several discussion periods interspersed between the
presentations.
9.1. Deﬁning biosimilarity
Dr. Kay asked Health Canada to clarify the distinction between
biosimilars and members of the same product class. For example,
golimumab and adalimumab are both human IgG anti-TNFa anti-
bodies, they have similar biological activities, bind the same ligand,
and bind the same Fc receptor. They are members of the same
product class but are not biosimilars or SEBs. Dr. Klein replied that
once an SEB is approved, it becomes a member of the same product
class as the RBD. Product labeling for SEBs will contain class-
speciﬁc warnings and precautions. As different products within
the same class, SEBs and RBDs have similar activities but are not
used interchangeably because they do not necessarily work the
sameway in the clinical setting. Dr. Ridgway continued, stating that
monoclonal antibodies in the same product class that have similar
targets and classes of immunoglobulin can have different clinical
effects. Health Canada is not intending to consider all products of
the same class roughly similar. Biosimilarity will be assessed on
a product-by-product basis. A sponsor would have to request the
review of a product as an SEB, and provide a substantial data
package to show biosimilarity to the RBD, including head-to-head
clinical data. In some circumstances the challenge of demon-
strating biosimilarity may be so great that it may be easier and less
expensive for a sponsor to request approval as a stand-alone
product via the New Drug Submission route rather than attempt-
ing to follow the route for SEBs.
Dr. Kay asked Health Canada whether it would be easier to
demonstrate biosimilarity for a smaller protein with good
biomarkers than for a large, complex monoclonal antibody. He
reviewed that glucagon and somatropin, which were approved
through the 505(b)(2) regulatory pathway in the US, have reliable
biomarkers, whereas many large biopharmaceuticals such as TNFa
inhibitors do not. Dr. Ridgway acknowledged that it will be very
challenging for monoclonal antibody or factor VIII/IX SEBs to follow
the SEB pathway due to the lack of understanding of howmolecular
attributes impact clinical efﬁcacy; however, as science evolves it
may be possible to produce enough data to show that many of the
variations between two molecules are not critical for safety or
efﬁcacy, allowing a focus on those that are.
Dr. Ridgway stated that SEBs using different manufacturing
processes than their respective RBDs are less likely to meet the
criteria for biosimilarity. Also, SEBs made in different host cell
systems may not be able to reference the safety record of their
respective RBDs due to differences in process-related and product-
related impurities.9.2. Clinical PK/PD studies
Dr. Kay asked whether conducting the PK/PD studies for SEBs
and RBDs in the same patient population would allow for a reliable
assessment of comparability. Dr. Mould replied that the reliability
of the datawould depend on the importance of receptor expression
levels for PK outcomes; highly variable responses in a subset of
patients in a small study could invalidate a determination of simi-
larity. This concern could be alleviated by using a large number of
subjects, or accounting for PD outcomes. For example, accounting
for differences in receptor expression levels over time or between
subjects may clarify the interpretation of PK data.
The types of single-dose or steady-state PK studies were also
discussed. Dr. Wang indicated that single-dose cross-over studies
are preferred, but that other study designs may be needed
depending on the properties of the molecule. For example, testing
in patient populations may require continued dosing for ethical
reasons. Dr. Mould asked if conﬁdence intervals for PK parameters
could be widened or narrowed depending on the therapeutic index
of the product being studied. Dr. Wang replied that, so far, wider
conﬁdence intervals have not been accepted. When asked by
Dr. Keystone about the lack of validated surrogate pharmacody-
namic markers of efﬁcacy in diseases such as rheumatoid arthritis,
Dr. Wang replied that, in such diseases, clinical trials would be
required for approval of an SEB.
9.3. Clinical safety and efﬁcacy studies
Dr. Wang stated that Health Canada recommends an equiva-
lence design for SEB clinical trials. Sponsors intending to use other
designs (e.g., non-inferiority) would have to provide justiﬁcation. A
non-inferiority approachwould require the sponsor to testwhether
the SEB demonstrated superiority, in which case it would not be
considered biosimilar. Dr. Feagan and Dr. Trudeau (oncologist,
Sunnybrook Health Sciences Centre, University of Toronto)
expressed concern regarding the large number of patients required
for equivalence trials and the capacity to conduct large clinical trials
in limited patient populations. With more companies shifting
clinical trials outside of North America, Dr. Kay asked whether data
obtained in such trials could be applied to North American pop-
ulations. Health Canada panelists conﬁrmed that clinical trial data
from outside Canada for new compounds and biosimilars is
acceptable, but justiﬁcation should be provided that the study
populations are relevant to the Canadian population. Dr. Mould
reminded the panel of the heterogeneity of clinical response that
can be observed in various racial backgrounds due to, for example,
variable expression of cytochrome P450 proteins, and that genetic
differences in the receptors targeted by biologic drugs have been
largely unexplored.
Dr. Feagan and Dr. Kay discussed suitable clinical trial endpoints,
and suggested that continuous outcomes (e.g., change in DAS28
over time in rheumatoid arthritis) rather than dichotomous
outcomes (e.g., ACR20 in rheumatoid arthritis or a fall of the
Crohn's Disease Activity Index (CDAI) of >70 points deﬁning
response in Crohn’s disease) may be more sensitive for the deter-
mination of clinical comparability.
9.4. Indication extrapolation
Dr. Trudeau asked Health Canada to clarify the clinical trial
requirements for a sponsor seeking approval of an SEB for different
disease states such as rheumatoid arthritis and ulcerative colitis.
Dr. Wang replied that Health Canada will not consider automatic
extrapolation. Indications will be considered on a case-by-case
basis according to data and scientiﬁc justiﬁcation provided by the
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disease states may pose a challenge to extrapolation of indications.
Health Canada was asked to comment on speciﬁc examples of
extrapolation of indications. In response to Dr. Trudeau, Dr. Wang
replied that it may be possible to extrapolate clinical data for
trastuzumab in the setting of metastatic disease to its use as
adjuvant therapy. However, the use of monotherapy or different
combination therapies in these settings would be important
considerations. In response to Dr. Keystone, Dr. Wang replied that it
may not be possible to extrapolate clinical data for a monoclonal
antibody in one rheumatologic indication to other rheumatologic
indications because of differences in dose, duration of therapy,
efﬁcacy of monotherapy vs. combination therapy, and stated claims
of efﬁcacy for those indications. However, extrapolation of indica-
tions may be granted if a sponsor provides sufﬁcient scientiﬁc
justiﬁcation and PK/PD data in the patient population of interest.
Dr. Feagan stated his opinion that efﬁcacy data in patients with
rheumatoid arthritis might not provide adequate justiﬁcation for
extrapolation to Crohn’s disease.
9.5. Manufacturing drift
Incremental differences between products may occur following
changes in manufacturing. Consequently, according to Dr. Ridgway,
after a thorough demonstration of biosimilarity at the time of
approval, an SEB and RBD may diverge to the point that they will
no longer be deemed biosimilar. Based on the potential for
manufacturing drift, the panel voiced concern regarding substitu-
tion or switching of products for individual patients.
Dr. Ridgway emphasized that regulatory controls are in place to
ensure comparability of stand-alone products before and after
manufacturing changes. Manufacturing changes to SEBs that occur
following approval will require the manufacturer to compare the
post-change SEB to the pre-change SEB to demonstrate that the
product has not changed signiﬁcantly. Innovator manufacturers
must meet the same requirements. Manufacturing changes to the
SEB will not trigger repeated comparability testing with the RBD;
therefore, a standard of comparability or biosimilarity that is ach-
ieved at the time of approval of the SEBmay not bemaintained over
time. Dr. Ridgway stated that physicians will need to consider the
appropriate medication for their patients because the outcomes of
an SEB and RBD can be different.
Dr. Keystone expressed the need to educate physicians about
product drift due to changes in manufacturing and the importance
of pharmacovigilance for biologic products.
9.6. Interchangeability
During the discussion on interchangeability it became clear that
Health Canada is taking a different approach from that of the FDA,
which is considering allowing interchangeability. Clariﬁcation was
requested by the panelists regarding the potential risks of inter-
changeability as a result of manufacturing drift.
Dr. Ridgway voiced that Health Canada does not support auto-
matic substitution of an SEB for its RBD and recommends that
physicians be involved in making decisions about substitution or
interchange. Physicians who switch a patient from an RBD to SEB
(or vice versa) would be advised to monitor the patient for adverse
effects. Physicians should be aware of patient-speciﬁc differences in
outcomes; therefore, a switch from innovator product to SEB should
be considered similar to switching between two innovator products.
Dr. Trudeau expressed concern about the potential pressure from
payers to prescribe lower-cost biologics once SEBs enter themarket,
and emphasized that Health Canada should ensure that SEBs meet
high standards so that physicians can feel conﬁdent using them.Dr. Ridgway commented that the decision to allow substitution
is in the hands of the provinces and territories which decide what
they will pay for. The colleges of pharmacy decide what their
pharmacists are allowed to dowithin a province. Dr. Guirguis asked
how Health Canada would respond if interchangeability and
substitution were to occur at the provincial or pharmacy level. In
response, Dr. Nyarko emphasized the need for education about
SEBs and biologics. For the only biosimilar product currently
approved in Canada (OMNITROPE), Health Canada issued a letter
that the product is not a generic drug and not deemed bio-
equivalent. Dr. Guirguis added that the provincial government of
Alberta has published a statement that SEBs will not be reviewed as
interchangeable products [43]. SEBs will go through the Common
Drug Review, and decisions from that review will be evaluated by
Alberta Health and an expert committee.
Dr. Keystone believed that physicians may not be aware of the
non-interchangeability of SEBs, and cautioned that product inter-
change or substitution may still occur in clinical practice or at the
pharmacy level unless there is regulatory guidance to prevent that
from happening. Panelists encouraged Health Canada to provide
clear guidance to clinicians and payers about the issue of
interchangeability.
9.7. Pharmacovigilance and nomenclature
Dr. Feagan asked Health Canada about the regulatory require-
ment for sponsors to maintain a database of patient exposure for
SEBs, as has been required for other biologic products. Dr. Wang
emphasized that the approachwill be similar to that as described in
ICH guidance, whereby the safety exposure required prior to
approval of a product will be a minimum of 100 patients for one
year. This requirement may increase depending on the post-
marketing safety record of the RBD, and the number of patients
required to ensure adequate statistical power for conclusions of
clinical biosimilarity.
Numerous concerns were raised regarding naming of SEBs, and
how post-approval adverse events would be attributed to SEBs or
RBDs. Dr. Kay suggested that unique names may be appropriate
for stand-alone products, and that unique names would be
needed in circumstances when using brand names is discouraged
or prohibited, such as in continuing medical education settings.
Dr. Keystone commented that an SEB and its RBD, which are not
identical, substitutable or interchangeable, could not be distin-
guished by using only the generic name.
Dr. Nyarko stated that SEBs would have unique brand names,
which can be used to identify products for pharmacovigilance
activities. For the purpose of differentiating between brands, the
WHO system for International Non-proprietary Names (INN) was
discussed [44], but Dr. Nyarko stated that this system poses
a number of challenges. Dr. Klein added that Health Canada
continues to consider the nomenclature of SEBs and is following
developments in other jurisdictions.
10. Closing remarks
This meeting provided Canadian stakeholders an opportunity to
gain clarity on Health Canada’s science-based guidance policy on
SEBs, and to discuss issues of concern from their perspective.
Although Health Canada, EMA, FDA and health agencies in other
regulatory jurisdictions take similar approaches to evaluating bio-
similars, there are requirements and policy positions speciﬁc to
Canada that Canadian stakeholders are beginning to appreciate. It is
hoped that this knowledge gap will continue to be bridged through
ongoing education and sharing of information among key Canadian
stakeholders and their international counterparts.
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